Qube Research & Technologies (QRT)’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,060	Closed	-$243K	–	3330
2022 Q1	$243K	Buy	+9,060	New	+$304K	﹤0.01%	1877
2021 Q2	–	Sell	-8,947	Closed	-$846K	–	2983
2021 Q1	$846K	Buy	+8,947	New	+$1.06M	0.01%	911
2020 Q3	–	Sell	-4,585	Closed	-$296K	–	2230
2020 Q2	$296K	Buy	+4,585	New	+$265K	﹤0.01%	1305

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TPTX Position: Q2 2022 in Review

Qube Research & Technologies (QRT) sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 9,060 shares — an estimated $243K sold.

Qube Research & Technologies (QRT) first reported a position in TPTX in Q2 2020 and held it in 3 quarters. The position peaked at $846K in Q1 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Qube Research & Technologies (QRT) reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 9,060 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $243K.
Qube Research & Technologies (QRT) first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Qube Research & Technologies (QRT)'s Turning Point Therapeutics, Inc. Common Stock position peaked at $846K in Q1 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2022, filed 15 Aug 2022.